Drug Pricing

Commentary

Putting Drug Prices on TV Will Cause Unnecessary Patient Panic

Last month, the Trump administration proposed several reforms to drive down prescription drug prices. One measure would force pharmaceutical companies to mention the sticker prices of their medicines in television advertisements. The new mandate covers all prescriptions drugs reimbursed by Medicare or Medicaid that cost more than $35 a month. The administration hopes this
Business & Economics

Wayne Winegarden Talks Drug Pricing Transparency on Lars Larson Show

Listen to PRI’s senior fellow in business and economics Dr. Wayne Winegarden discuss President Trump’s drug pricing transparency proposal on the nationally-syndicated “Lars Larson Show.”  The interview begins at the 54:25 mark.
Blog

Does President Trump Favor Price Controls?

At 2 pm Eastern time today, President Trump spoke at the Department of Health and Human Services where he recommended a litany of policies that would ultimately impose price controls on the pharmaceutical market. Take his proposal to force the prices paid by Medicare for drugs administer in doctors’ offices
Commentary

Drug prices in ads actually hurt consumers

This month, the Trump administration proposed a new rule that would require advertisements for prescription drugs covered by Medicare or Medicaid to include the list price of the medicine. To be sure, a free market is dependent on consumers making informed decisions. But this move would provide patients with incomplete, misleading numbers
Business & Economics

Wayne Winegarden Talks Drug Pricing Advertising on Newsmax TV

Watch PRI’s Wayne Winegarden discuss the Trump Administration proposal on drug pricing advertising on “America Talks Live” with Dr. Gina Loudon and John Cardillo on Newsmax TV.
Commentary

Where’s the Outrage?

How can you tell if competition is working in a given market? Generally speaking, prices go down while quality goes up. Productivity increases as more efficient methods are discovered. Shortages are rare to nonexistent. And, most important, consumers win. Government intervention, monopolies, and other market distortions can disrupt the normal
Commentary

Why Health-Care Mergers Aren’t So Scary

Prominent politicos are voicing concerns about the wave of impending mergers in the health-care industry. On August 1, California insurance commissioner Dave Jones urged the Justice Department to block the merger of Aetna and CVS, fretting it “will have anticompetitive effects and … harm consumers.” Days later, the American Medical Association echoed his concerns.
Commentary

Single-Payer Progressives Lie Their Way to Victory

November’s midterm elections are just around the corner. This fall, Democratic congressional candidates are betting the farm — or shall we say the House — on government-run health care. The crop of Democrats eyeing the presidency in 2020, meanwhile, is similarly united behind a government takeover of the U.S. healthcare
Drug Importation

Sally Pipes in Health Care News Article on Drug Imports

Trump Administration Considers Allowing Some Drug Imports By Christopher Talgo U.S. Health and Human Services (HHS) Secretary Alex Azar has directed the Food and Drug Administration (FDA) to establish a working group to weigh the risks and rewards of drug importation, which is currently banned in the United States. The
Business & Economics

It’s Generics Not PBMs That Keep Pharmaceuticals Affordable

Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however. Not only did the growth in prescription drugs expenditures slow to 1.3 percent in 2016, longer-term (between 2009 and 2016), the average annual growth
Commentary

Putting Drug Prices on TV Will Cause Unnecessary Patient Panic

Last month, the Trump administration proposed several reforms to drive down prescription drug prices. One measure would force pharmaceutical companies to mention the sticker prices of their medicines in television advertisements. The new mandate covers all prescriptions drugs reimbursed by Medicare or Medicaid that cost more than $35 a month. The administration hopes this
Business & Economics

Wayne Winegarden Talks Drug Pricing Transparency on Lars Larson Show

Listen to PRI’s senior fellow in business and economics Dr. Wayne Winegarden discuss President Trump’s drug pricing transparency proposal on the nationally-syndicated “Lars Larson Show.”  The interview begins at the 54:25 mark.
Blog

Does President Trump Favor Price Controls?

At 2 pm Eastern time today, President Trump spoke at the Department of Health and Human Services where he recommended a litany of policies that would ultimately impose price controls on the pharmaceutical market. Take his proposal to force the prices paid by Medicare for drugs administer in doctors’ offices
Commentary

Drug prices in ads actually hurt consumers

This month, the Trump administration proposed a new rule that would require advertisements for prescription drugs covered by Medicare or Medicaid to include the list price of the medicine. To be sure, a free market is dependent on consumers making informed decisions. But this move would provide patients with incomplete, misleading numbers
Business & Economics

Wayne Winegarden Talks Drug Pricing Advertising on Newsmax TV

Watch PRI’s Wayne Winegarden discuss the Trump Administration proposal on drug pricing advertising on “America Talks Live” with Dr. Gina Loudon and John Cardillo on Newsmax TV.
Commentary

Where’s the Outrage?

How can you tell if competition is working in a given market? Generally speaking, prices go down while quality goes up. Productivity increases as more efficient methods are discovered. Shortages are rare to nonexistent. And, most important, consumers win. Government intervention, monopolies, and other market distortions can disrupt the normal
Commentary

Why Health-Care Mergers Aren’t So Scary

Prominent politicos are voicing concerns about the wave of impending mergers in the health-care industry. On August 1, California insurance commissioner Dave Jones urged the Justice Department to block the merger of Aetna and CVS, fretting it “will have anticompetitive effects and … harm consumers.” Days later, the American Medical Association echoed his concerns.
Commentary

Single-Payer Progressives Lie Their Way to Victory

November’s midterm elections are just around the corner. This fall, Democratic congressional candidates are betting the farm — or shall we say the House — on government-run health care. The crop of Democrats eyeing the presidency in 2020, meanwhile, is similarly united behind a government takeover of the U.S. healthcare
Drug Importation

Sally Pipes in Health Care News Article on Drug Imports

Trump Administration Considers Allowing Some Drug Imports By Christopher Talgo U.S. Health and Human Services (HHS) Secretary Alex Azar has directed the Food and Drug Administration (FDA) to establish a working group to weigh the risks and rewards of drug importation, which is currently banned in the United States. The
Business & Economics

It’s Generics Not PBMs That Keep Pharmaceuticals Affordable

Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however. Not only did the growth in prescription drugs expenditures slow to 1.3 percent in 2016, longer-term (between 2009 and 2016), the average annual growth
Scroll to Top